Disruption of the CRF2 receptor pathway decreases the somatic expression of opiate withdrawal

Neuropsychopharmacology

Volumn 33, Issue 12, 2008, Pages 2878-2887

  Papaleo, Francesco ^a,c   Ghozland, Sandy ^b   Ingallinesi, Manuela ^a   Roberts, Amanda J ^b   Koob, George F ^b   Contarino, Angelo ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

CRF system; CRF2 receptor; Drug dependence; Mice; Opiate withdrawal

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; MORPHINE; NALOXONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; FEMALE; MOTIVATION; MOUSE; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYMPTOM; TREMOR; WET DOG SHAKES; WITHDRAWAL SYNDROME;

EID: 53949107198     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.8     Document Type: Article

References (54)

1. Baker TB, Piper ME, McCarthy DE, Majeskie MR, Fiore MC (2004). Addiction motivation reformulated: an affective processing model of negative reinforcement. Psychol Rev 111: 33-51.
2. Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE et al (2000). Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 24: 410-414.
3. Bale TL, Vale WW (2003). Increased depression-like behaviors in corticotropin-releasing factor receptor-2-deficient mice: sexually dichotomous responses. J Neurosci 23: 5295-5301.
4. Bale TL, Vale WW (2004). CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 44: 525-557.
5. Carrera MR, Schulteis G, Koob GF (1999). Heroin self-administration in dependent Wistar rats: increased sensitivity to naloxone. Psychopharmacology (Berl) 144: 111-120.
6. Cicero TJ, Nock B, Meyer ER (2002). Gender-linked differences in the expression of physical dependence in the rat. Pharmacol Biochem Behav 72: 691-697.
7. Contarino A, Dellu F, Koob GF, Smith GW, Lee KF, Vale W et al (1999). Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res 835: 1-9.
8. Contarino A, Gold LH (2002). Targeted mutations of the corticotropin-releasing factor system: effects on physiology and behavior. Neuropeptides 36: 103-116.
9. Contarino A, Papaleo F (2005). The corticotropin-releasing factor receptor-1 pathway mediates the negative affective states of opiate withdrawal. Proc Natl Acad Sci USA 102: 18649-18654.
10. Coste SC, Heard AD, Phillips TJ, Stenzel-Poore MP (2006). Corticotropin-releasing factor receptor type 2-deficient mice display impaired coping behaviors during stress. Genes Brain Behav 5: 131-138.
11. Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH et al (2000). Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 24: 403-409.
12. Erb S, Shaham Y, Stewart J (1998). The role of corticotropin-releasing factor and corticosterone in stress- and cocaine-induced relapse to cocaine seeking in rats. J Neurosci 18: 5529-5536.
13. Funk CK, Zorrilla EP, Lee MJ, Rice KC, Koob GF (2007). Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biol Psychiatry 61: 78-86.
14. Gellert VF, Holtzman SG (1978). Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J Pharmacol Exp Ther 205: 536-546.
15. Gonzalez G, Oliveto A, Kosten TR (2004). Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother 5: 713-725.
16. Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P et al (2002). 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3- fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301: 333-345.
17. Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM (2003). International union of pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev 55: 21-26.
18. Heinrichs SC, Menzaghi F, Pich EM, Baldwin HA, Rassnick S, Britton KT et al (1994). Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity. Neuropsychopharmacology 11: 179-186.
19. Henry B, Vale W, Markou A (2006). The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J Neurosci 26: 9142-9152.
20. Ho SP, Takahashi LK, Livanov V, Spencer K, Lesher T, Maciag C et al (2001). Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor. Brain Res Mol Brain Res 89: 29-40.
21. Hodgson RA, Higgins GA, Guthrie DH, Lu SX, Pond AJ, Mullins DE et al (2007). Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression. Pharmacol Biochem Behav 86: 431-440.
22. Houshyar H, Manalo S, Dallman MF (2004). Time-dependent alterations in mRNA expression of brain neuropeptides regulating energy balance and hypothalamo-pituitary-adrenal activity after withdrawal from intermittent morphine treatment. J Neurosci 24: 9414-9424.
23. Kenny PJ, Chen SA, Kitamura O, Markou A, Koob GF (2006). Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J Neurosci 26: 5894-5900.
24. Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F et al (2000). Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 24: 415-419.
25. Kreek MJ, LaForge KS, Butelman E (2002). Pharmacotherapy of addictions. Nat Rev Drug Discov 1: 710-726.
26. Linseman MA (1977). Naloxone-precipitated withdrawal as a function of the morphine-naloxone interval. Psychopharmacology (Berl) 54: 159-164.
27. Lu L, Chen H, Su W, Ge X, Yue W, Su F et al (2005). Role of withdrawal in reinstatement of morphine-conditioned place preference. Psychopharmacology (Berl) 181: 90-100.
28. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I et al (1996). Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383: 819-823.
29. Mucha RF, Kalant H, Linseman MA (1979). Quantitative relationships among measures of morphine tolerance and physical dependence in the rat. Pharmacol Biochem Behav 10: 397-405.
30. Muller MB, Zimmermann S, Sillaber I, Hagemeyer TP, Deussing JM, Timpl P et al (2003). Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci 6: 1100-1107.
31. NIDA (2005). Monitoring the future: national results on adolescent drug use. Available at http://www.monitoringthefuture.org. Accessed May 2007.
32. Nielsen DM, Carey GJ, Gold LH (2004). Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. Eur J Pharmacol 499: 135-146.
33. O'Brien CP (1996). Drug addiction and drug abuse. In: Hardman JG, Limbird LE (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill: New York. pp 557-577.
34. OEDT (2006). European Monitoring Centre for Drugs and Drug Addiction. Annual Report 2006. Available at http://www.emcdda.europa.eu. Accessed May 2007.
35. Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Nakazato A et al (1999). Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J Pharmacol Exp Ther 289: 926-935.
36. Papaleo F, Contarino A (2006). Gender- and morphine dose-linked expression of spontaneous somatic opiate withdrawal in mice. Behav Brain Res 170: 110-118.
37. Papaleo F, Kitchener P, Contarino A (2007). Disruption of the CRF/CRF(1) receptor stress system exacerbates the somatic signs of opiate withdrawal. Neuron 53: 577-589.
38. Radulovic J, Ruhmann A, Liepold T, Spiess J (1999). Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J Neurosci 19: 5016-5025.
39. Risbrough VB, Hauger RL, Pelleymounter MA, Geyer MA (2003). Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (Berl) 170: 178-187.
40. Risbrough VB, Hauger RL, Roberts AL, Vale WW, Geyer MA (2004). Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. J Neurosci 24: 6545-6552.
41. Rivier C, Vale W (1983). Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature 305: 325-327.
42. Ruiz F, Fournie-Zaluski MC, Roques BP, Maldonado R (1996). Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism. Br J Pharmacol 119: 174-182.
43. Sarnyai Z, Biro E, Gardi J, Vecsernyes M, Julesz J, Telegdy G (1995). Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. Brain Res 675: 89-97.
44. Schulteis G, Koob GF (1996). Reinforcement processes in opiate addiction: a homeostatic model. Neurochem Res 21: 1437-1454.
45. Shaham Y, Shalev U, Lu L, De Wit H, Stewart J (2003). The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 168: 3-20.
46. Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH et al (1998). Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20: 1093-1102.
47. Stinus L, Cador M, Zorrilla EP, Koob GF (2005). Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology 30: 90-98.
48. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul JM, Stalla GK et al (1998). Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 19: 162-166.
49. Valdez GR, Inoue K, Koob GF, Rivier J, Vale W, Zorrilla EP (2002a). Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res 943: 142-150.
50. Valdez GR, Roberts AJ, Chan K, Davis H, Brennan M, Zorrilla EP et al (2002b). Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor. Alcohol Clin Exp Res 26: 1494-1501.
51. Valdez GR, Sabino V, Koob GF (2004). Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotropin- releasing factor-2 receptor activation. Alcohol Clin Exp Res 28: 865-872.
52. Valdez GR, Zorrilla EP, Rivier J, Vale WW, Koob GF (2003). Locomotor suppressive and anxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasing factor agonist. Brain Res 980: 206-212.
53. Venihaki M, Sakihara S, Subramanian S, Dikkes P, Weninger SC, Liapakis G et al (2004). Urocortin III, a brain neuropeptide of the corticotropin-releasing hormone family: modulation by stress and attenuation of some anxiety-like behaviours. J Neuroendocrinol 16: 411-422.
54. Zorrilla EP, Valdez GR, Nozulak J, Koob GF, Markou A (2002). Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res 952: 188-199.